Resumen

GONZALEZ-MACIAS, Jesús  y  OLMOS-MARTINEZ, José Manuel. Romosozumab: confusion regarding its indications. Rev Osteoporos Metab Miner [online]. 2023, vol.15, n.2, pp.81-87.  Epub 25-Sep-2023. ISSN 2173-2345.  https://dx.doi.org/10.20960/revosteoporosmetabminer.00011.

Romosozumab is undoubtedly an excellent drug to treat osteoporosis. However, its high price—much higher than antiresorptive drugs—initially led to accepting that its indication should be limited to patients with particularly high risk of fracture. However, the implementation of this idea into the routine clinical practice has been challenging. Firstly, different terms (“very high risk”, “high risk”, “severe osteoporosis”) have been used to describe such indications, and the specific meaning of each term changes from one author to the next. On the other hand, without enough scientific basis, concepts have been introduced to expand the drug indications to the point of proposing its universal or near-universal use (“imminent risk”, initiation of anabolic treatment for osteoporosis universally or quasi-universally). All this has created confusion among prescribing physicians and led to overly restrictive regulations imposed by health authorities regarding its use. This manuscript delves into these and other ideas in detail.

Palabras clave : Romosozumab; Trials; Osteoporotic fracture.

        · resumen en Español     · texto en Español | Inglés     · Español ( pdf ) | Inglés ( pdf )